tradingkey.logo

Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications

ReutersApr 21, 2025 11:50 AM

- Immunovant Inc IMVT.O:

  • IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJÖGREN’S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402

  • IMMUNOVANT INC - ERIC VENKER APPOINTED AS CEO OF IMMUNOVANT

  • IMMUNOVANT INC - TIAGO GIRAO APPOINTED AS CFO OF IMMUNOVANT

  • IMMUNOVANT INC - IND CLEARED FOR IMVT-1402 IN SJD, STUDY TO INITIATE SUMMER 2025

  • IMMUNOVANT INC - CURRENT CASH BALANCE PROVIDES RUNWAY THROUGH GRAVES’ DISEASE READOUT IN 2027

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI